MMV’s key achievements over the last 15 years

1999: Malaria killed over 1 million people, hitting poor people hardest

2000: MMV launched a new phase III project to develop new antimalarials for vulnerable populations

2001: MMV launched a new alliance with industry and academia: GSK, University of Oxford and London School of Hygiene & Tropical Medicine

2003: 1st patient enrolled in an MMV-supported trial; the site in Burkina Faso is also the 1st to receive MMV capacity-building support

2004: Agreement signed with Sigma-Tau, Oxford University and Holley Chlor to develop Coartem® Dispersible

2005: Agreement signed with Novartis to develop Coartem® Dispersible

2006: Major phase III studies completed for Coartem® and Parastar® involving 15,000+ patients in Côte d’Ivoire

2007: MMV, UNHCR and Sanofi launch largest post-launch antimalarial safety study of Coartem®/AQAM® involving 15,000+ patients

2008: 1st medicines: Coartem® Dispersible (partner Novartis) – 1st rigorously approved child-friendly ACT

2009: 6 million compounds screened directly against the parasite by MMV and partners, yielding 25,000+ new chemical starting points

2010: 1st medicines: Coartem® Dispersible (partner Novartis) – 1st rigorously approved child-friendly ACT

2011: 1st medicines: Pyramax® for uncomplicated malaria (partner Shering-Plough) receives positive scientific opinion from EMA

2012: 4th medicines: Pyramax® for uncomplicated malaria (partner Shering-Plough) receives positive scientific opinion from EMA

2013: 1st molecules with potential for chemotherapy (KAF156 with Novartis and DHA-QFL with Novartis) enter clinical development

2014: Controlled Human Malaria Infection Model comes on stream at QIMR Berghofer

Global malaria mortality down by 47% from 2000

1 donor dollar = USD 3.5 investment impact thanks to direct and in-kind support

9 new medicines in clinical development, prioritizing eradication and the needs of vulnerable populations

Malaria Box delivered to 50+ countries

Fifty new medicines, 36 million vials of Artesun® delivered, estimated to have saved an additional 200,000–240,000 lives compared to treatment with quinine

FIRST PLEDGES BY MMV DONORS


2001: Norwegian Agency for Development Corporation, Rockefeller Foundation

2002: BiH billion, United States Agency for International Development, Welcome Trust

2003: BiH billion, United States Agency for International Development

2004: BiH billion, United States Agency for International Development

2005: BiH billion

2006: BiH billion

2007: BiH billion

2008: BiH billion

2009: BiH billion

2010: BiH billion

2011: BiH billion

2012: BiH billion

2013: BiH billion

2014: BiH billion

MMV: Medicines for Malaria Venture

ZBI+ copies of the Malaria Box delivered to research groups globally

1st antimalarial molecule discovered by an African-led team, MMV045, helps human trials

Tafenoquine to treat the liver-stage of relapsing malaria enters phase III

DZ439 and piperaquine, a potent single-exposure antimalarial combination enters phase IIb

250 million courses of Coartem® Dispersible delivered to treat children in 50 countries

National Science and Technology Development Agency (NSTDA), Thailand